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Introduction: Esophagectomy is a major surgery with a high degree of catabolic and post-surgical inflammatory response
accompanied by high morbidity and significant mortality. Post-surgical nutritional support via enteral administration of v-3 fatty acids
has been seen to be effective although its bad tolerance. There are few clinical trials with parenteral v-3 fatty acids in these patients.
We propose to investigate the effect of combining a parenteral fish oil lipid emulsion with the standard enteral nutrition (EN) support.
Materials and methods: Prospective, single-center, randomized, double-blind study in esophagectomized patients, and
treated after surgery with parenteral lipid emulsions of v-3 fatty acids or a mixture of v-6 long-chain triglycerides/short-chain
triglycerides 50%. These emulsions will be added to the standard nutritional support in continuous infusion until 5days of treatment
have been completed. Patients will be randomized 1:1:1 in Group A receiving 0.4g/kg/d of fish-oil lipid emulsion and 0.4g/kg/d of a
lipid emulsion mixture of v-6 long-chain fatty acids (LCT) plus medium-chain fatty acids (MCT) (total dose of 0.8g/kg/d of lipid
emulsion); Group B receiving 0.8g/kg/d of fish oil lipid emulsion and Group C receiving 0.8g/kg/d of LCT/MCT emulsion.
The main objective is to determine whether 5days administration of intravenous v-3 fatty acid lipid emulsion is effective in
normalizing interleukin-6 levels compared with LCT/MCT emulsions, and whether a 0.8g/kg/d dose is more effective than 0.4g/kg/d.
Secondary outcomes include other inflammatory markers such as C-reactive protein, tumor necrosis factor alpha and interleukin-10,
and parameters of morbidity, safety, nutrition and mortality.ata will be collected in a database where patients will be codified with an assigned consecutive number, avoiding the use of any clinical history number or initials, and
ereby ensuring data protection. All participating patients will have signed an informed consent form following the recommendations of RD 223/04. Clinical treatment
ill be in accordance with good clinical practice. Confidentiality will be guaranteed following the Organic Law of Personal Data Protection 15/99. This trial has been
pproved by the Ethics Committee of Clinical Investigation of our Hospital and by the Spanish Agency of Drugs and Sanitary Products, see document of ethical
pproval as Supplemental Digital Content in the submission, http://links.lww.com/MD/G205).
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Suárez-Lledó et al. Medicine (2021) 100:25 MedicineSamples will be collected at the time when surgery is indicated and on days 0, 1, 3, 5 and 21 to determine inflammatory, nutritional,
hepatic and safety parameters. In addition, clinical follow-up will be continued throughout the hospital admision and up to 1 year after
surgery.
Discussion:Studies of v-3 fatty acids administered parenterally in esophagectomized patients are scarce. This study proposes to
investigate the effect of combining fish-oil lipid emulsions administered parenterally with EN support. Potential benefits include fast
incorporation of lipids to the cellular membranes and to the inflammatory cascade, and the use of only 1 pharmaconutrient.
Trial Registration: FAR-NP-2017-01 EudraCT number: 2016-004978-17.
https://reec.aemps.es/reec/public/detail.html searching the EudraCT number.
Version Identifier: Version 2, 08/06/2017.
Abbreviations: BMI = body mass index, EN = enteral nutrition, EPG = esophagectomy, IC = informed consent, IL-10 =
interleukin-10, IL-6= interleukin-6, IL-8 = interleukin-8, LCT = v-6 long-chain fatty acids, MCT =medium-chain fatty acids, SPIRIT =
Standard Protocol Items: Recommendations for Interventional Trials, TNF-a = tumoral necrosis factor-a.
Keywords: anti-inflammatory, esophageal cancer, esophagectomy, fish-oil, immunomodulation, omega-31. Introduction
Esophageal cancer incidence increases with age, is more prevalent
in men and is associated with risk factors such as smoking habit,
obesity and alcoholism.[1]
This cancer is frequently associated with protein-energy
malnutrition[2] and usually has a poor prognosis due to late
presentation and diagnosis, as well as patients not meeting
criteria for curative treatment at the time of diagnosis. About 1 in
5 patients needs surgical resection.
Esophagectomy (EPG) is a major surgical intervention which
involves total or partial esophageal resection and restoration of
gastrointestinal continuity.[1] Despite improvements in perioper-
ative care, EPG continues to be associated with high rates of
morbidity and mortality.[1,2] In fact, post-operative complica-
tions are common, including both primary surgical events, such
as anastomosis dehiscence or chylothorax, and adverse medical
events, principally pneumonia.[1,2]
Nutritional support therapy is important in these patients due
to the malnutrition associated with this pathology. Additionally,
some enterally administered pharmaconutrients have been shown
to be effective in the reduction of post-operative complications.[2]
Recent studies show that early enteral nutrition (EN) has other
benefits: it increases immunocompetence, reduces infection rates
and maintains intestinal functionality and structure. EN is
cheaper and safer than parenteral nutrition, however post-
operative EN is associated with tolerance problems such as:
diarrhea, abdominal distension, and paralytic ileus or nausea,
and only 50 percent of patients achieve their nutritional
objective.[3] Sometimes, symptoms become worse when caloric
intake is increased, and EN discontinuation may be necessary.[4]
Omega-3 fatty acids, the principal components of which are
eicosapenthaenoic acid and docosahexaenoic acid, are one of the
pharmaconutrients with beneficial effects in post-operative
morbidity. They are essential polyunsaturated fatty acids and
fish oil derivates. Their administration can reduce proinflamma-
tory cytokine production and regulate eicosanoid synthesis.[5–7]
Immunomodulation withv-3 fatty acid based nutritional therapy
has demonstrated benefits in reducing infectious post-operative
complications and length of stay in elective gastrointestinal
surgery patients, particularly in those who present with
preoperative malnutrition.[8,9] The enteral administration of
v-3 fatty acids in esophagectomized patients has been assessed in
different studies.[3,10–12] These assays verify the variability in the2
assimilation of v-3 fatty acids when they are administered
enterally, and show different results in relation to post-operative
morbidity. However, 2 meta analyses[13,14] conclude that enteral
immunonutrition improves patient’s morbidity without modify-
ing their mortality.
The physiological role of v-3 fatty acids is extensively reported,
not only in maintaining nutritional homeostasis but also in the
resolution of inflammatory mechanisms[15] and in the course of
inflammatory pathologies such as atherosclerosis or cancer. The
effects of v-3 fatty acid administration in the metabolic response
are still being explored and discovered. Due to their protective
effect in inflammatory processes such as colitis, ischemia-
reperfusion syndrome, pain, sepsis or acute pulmonary pathology,
the role of v-3 fatty acids is relevant in artificial nutrition support.
PUFAs are precursors of proinflammatory as well as anti-
inflammatory secondary messengers, and the physiological
response produced depends on the balance of the lipid
composition of the membrane. The eicosanoids derived from
these polyunsaturated fatty acids present receptors in different
kinds of cells executing different physiological functions. The
study of these secondary messengers in the esophagectomized
patient, may establish their correlation with the patient’s clinical
pathway depending on the capacity of the v-3 fatty acids to
modulate these secondary messengers.
Due to their iso-osmolarity, intravenous administration of lipid
emulsions (LE) does not require a central line thereby avoiding
any extra invasive treatment for the patient. In fact, LE may have
protective properties for the vascular wall. Moreover, in patients
considered for the study, the LE could be administered
simultaneously with EN, so that gastrointestinal tract stimulation
will not be interrupted, and the caloric goal achieved.
Studies of v-3 fatty acids administered parenterally in
esophagectomized patients are poorly reported in the literature.
This study proposes to investigate the effect of combining fish-oil
lipid emulsions administered parenterally with EN support in the
framework of a randomized clinical trial. The difference between
this approach and previous published studies is 2-fold:- Parenteral administration facilitates fast incorporation of lipids
to the cellular membranes, and consequently to the inflamma-
tory cascade.[16]- Use of only 1 parenteral pharmaconutrient (v-3 fatty acids)
facilitates the caloric goal and enables the study of the
immunomodulatory effect of 1 nutrient without interference
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enterally, the commercialized products available are combina-
tions of different immunonutrients. Lipid emulsion comprising
combined long-chain v-6 long-chain fatty acids (LCT) and
medium-chain fatty acids (MCT) is proposed as a control lipid
to compare the effects on immunomodulation. These emulsions
have the same physical appearance as v-3 lipid emulsion. The
LCT emulsions have an active role in the immunological system
but are sensitive to peroxidation, whereas MCT emulsions do
not participate in the immune response and are not sensitive
to peroxidation, so in consequence the combination of both has
no immunomodulatory effect.[17]
2. Methods
This trial is a prospective, single-center, randomized, double-
blind study in patients diagnosed with esophageal cancer who
post-EPG are treated with a lipid emulsion of v-3 fatty acid or a
mixture of v-6 long-chain triglycerides/short-chain triglycerides
50%.2.1. Study objectives
The main objective of this study is: To establish if the endovenous administration of v-3 fatty-acid
fish-oil lipid emulsions for 5days in esophagectomized patients
is effective in reducing inflammation – measured as seric
concentration of interleukin-6 (IL-6) – compared to the
administration of lipid emulsions of LCT/MCT. Additionally,
to determine if doses of 0.8g/kg/d are more effective than doses
of 0.4g/kg/d in the normalization of IL-6.
The secondary objectives aim to determine if the intravenous
administration of v-3 fatty-acid fish-oil lipid emulsions for 5days
in esophagectomized patients shows differences compared with
the administration of LCT/MCT lipid emulsion with regard to: Seric concentration of other inflammatory parameters: C-
reactive protein, tumoral necrosis factor-a (TNF-a), interleu-
kin-10 (IL-10), interleukin-8 (IL-8) and soluble interleukin-2
receptor. In addition, in the follow-up, whether these markers,
alone or in combination, show equal or greater efficacy of effect
on the inflammatory response compared to IL-6. Post-operative complications: suture dehiscence, chylotorax,
pneumonia and other infections. Safety, measured as hepatic impairment and alterations in
coagulation parameters. Nutritional parameters: albumin, prealbumin and lympho-
cytes. Mortality: evaluated at hospital admission and at 1 year post-
surgical intervention.
2.2. Study design
Prospective, unicentric, randomized, double-blinded study in
patients with esophageal cancer and esophagectomized by the
Ivor-Lewis or McEwan techniques. The study will be carried out
in accordance with the good clinical practice in our hospital.
All participants will receive a lipid emulsion by continuous
infusion in addition to EN support for 5days post-surgery. The
standard EN support will be initiated with Impact Neutre 500ml
(a normocaloric, hyperproteic and immunomodulatory diet3
composed of 3.9g of lipids in each 100ml, 1.8g of MCT/
100ml, 0.61g of v-6 fatty acids/100ml and 0.6g of v-3 fatty
acids/100ml, with a caloric input of 144 kcal/100ml daily); it
will be initiated at 21ml/h and titrated to 1500ml daily. When
the body mass index (BMI) is greater than 25, the ideal adjusted
body weight will be applied following the formula:
“Ideal adjusted body weight = ideal body weight + (actual
body weight - ideal body weight) ∗ 0.25 (if BMI 26–30) or ∗0.5
(if BMI>30)”.
Group A will receive a lipid emulsion mixture of 0.4g/kg/d of
fish-oil and 0.4g/kg/d of LCT/MCT, Group B will receive 0.8g/
kg/d of fish-oil lipid emulsion and Group C will receive a lipid
emulsion mixture of 0.8g/kg/d of LCT plus MCT 50% (view at
Fig. 1, which illustrates the diagram flowchart of this study)
This study will be conducted in accordance with Good Clinical
Practice and this protocol follows the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) checklist
(Fig. 2 and Additional file 1, which shows the suitability of this
study with the SPIRIT guidelines, Supplemental Digital Content,
http://links.lww.com/MD/G206).
2.2.1. Study population. Patients diagnosed with esophageal
cancer and candidates for EPG by the Ivor-Lewis or MacEwan
techniques, and who meet the following inclusion criteria:1. 18years old or older, any gender and any race.
2. Willing and able to give their written informed consent (IC) for
the study. If a subject is unable to give written IC, his legal
representative may do so in his/her place.3. Having access to the digestive tract.
Patients who meet the following exclusion criteria will not be
chosen:1. Hypersensitivity type 1 or idiosyncratic reactions to any of the
lipid emulsion components.2. Pregnant or breastfeeding women.
3. Plasmatic triglycerides concentration >3mmol/L.
4. In receipt of chronic treatment with corticosteroids or
immunosuppressants in the last month.
5. HIV diagnosis.
6. Transplanted.
7. Hepatic impairment classified as Child-Pugh grade B (signifi-
cative functional compromise) or grade C (decompensated
disease).
2.2.1.1. Subject and/or treatment withdrawal criteria. Patients
can voluntarily refuse to continue in the study at any time. In
addition, presentation of any adverse effect related to the
treatment will lead to a treatment withdrawal and to exclusion
from the study.
All patients who present with surgical complications classifi-
able as grade IV of the Dindo-Clavien classification[18] will be
excluded from the study.
2.2.2. Patients recruitment, randomization and allocation.
All patients allocated for EPG following medical criteria, and
those who meet the inclusion criteria will be candidates to
participate in the trial.
The surgical team will be responsible for communicating the
possibility of participating in this trial when IC is obtained for
the surgical intervention. IC for participation in this trial will be
collected before randomization.
Figure 1. Study design flow chart.
Suárez-Lledó et al. Medicine (2021) 100:25 MedicineSubjects will be randomized to 3 groups (1:1:1) by a
pharmaceutical researcher after recruitment by the surgical team: Group Awill receive 0.4g/kg/d of fish-oil LE and 0.4g/kg/d of a
LEmixture LCT/MCT receiving a total dose of 0.8g/kg/d of LE
over 5days post-surgery, Group B will receive 0.8g/kg/d of fish-oil LE,
 And Group C will receive 0.8g/kg/d of a LE mixture of LCT/
MCT 50%.
This allocation will be blind for all patients and health
personnel. The allocation sequence (computer-generated random
numbers) will be generated by the pharmaceutical researcher and
it will be performed by randomized blocks permutated with the
block size defined at random. In the first step, blocks of size 3 with
possible sequences ABC, ACB, CAB and CBA, and size 6 will be
defined. In a second step the clusters will be randomized, and in a
third step the sequences will be randomized within the blocks.
This method ensures that the groups are balanced throughout the
study, and that the researcher cannot predict the sequence. The
pharmaceutical researcher will be responsible for patient
assignation to the corresponding intervention group, and will
also assign a numbered patient identification code for each
patient in the trial. The composition of the emulsion administered4
to each patient will only be known by: the pharmaceutical
researcher responsible for clinical trials, the pharmaceutical
researcher who will validate its conduct, and the personnel who
will conduct it.
2.2.3. Number of participants subjects and trial duration:.
Recruitment will last a total of 24months from the approval date.
Each subject will participate in the trial for a year post-surgical
intervention.
On the basis of the results obtained and as referenced by
Furukawa et al[19] (a study of the values of IL6 in
esophagectomized patients who received parenteral nutrition
with v-6 fatty acids or without lipids), and considering
that the effect of administration of fish-oil emulsion (with v-3
fatty acids) will be similar to the non-administration of v-6
fatty acids, a sample size of 33 patients is estimated for 80%
of potency and 5% of alfa error with 10% of anticipated
losses.2.3. Study variables
The main variable of this study is the variation of seric
concentration levels of IL6 at randomization and on days 1, 3,
Figure 2. Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) flowchart.
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lipid emulsions parenterally for 5days compared with those
receiving LCT/MCT emulsions.
The secondary variables will examine whether intravenous
administration of fish-oil lipid emulsions instead of LCT/
MCT for 5days leads to differences from randomization
and on days 1, 3, 5 and 21 post-randomization with respect
to: Seric concentrations of inflammatory markers: RCP, TNF-a,
IL-10, IL-8 and soluble interleukin-2 receptor. Morbidity measured as post-operative complications: suture
dehiscence, chylotorax, pneumonia and other infections. Safety measured as hepatic impairment (total bilirubin, alanin-
aminotranspherase, aspartate-amino transpherase, gammaglu-
tamil transpherase, alkaline phosphatase) and alteration in
coagulation parameters (INR, prothrombin time, platelet
count). Nutritional parameters: albumin, prealbumin and lympho-
cytes. Mortality measured for a year after surgical intervention.5
2.4. Treatments used in the trial
2.4.1. Research drugs. The fish-oil emulsion employed in the
study is commercialized as Omegaven, and the mixture emulsion
of LCT/MCT is commercialized as Lipofundina
Lipids emulsions will be prepared at the Pharmacy Department
with the same aseptic conditions used for NP (in a laminar flow
cabinet). They will be delivered ready for administration in a
multilayer bag, and will be stored and conserved in accordance
with the normal procedures of the department of Pharmacy. The
double blind will be facilitated by the identical galenic
presentation of the lipid emulsions.
Emulsions will be dispensed when the trial recipe used in the
University Hospital of Bellvitge is finalised.
2.4.2. Others concomitant treatments. During this trial both
the patient’s usual medication and any support medication
needed during admission will be maintained as usual.
2.5. Data collection
2.5.1. Demographic, pharmacological, clinical and analyti-
cal data. Demographics, clinical and analytical data generated
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in the Data Collection Logbook.
Demographic data: age, gender, body weight, height and BMI
will be recorded.
Pharmacological data: any adjuvant chemotherapy received by
a patient after trial treatment will be recorded specifying the
treatment scheme.
2.5.1.1. Analytical data.- Inflammatory parameters: values of IL-6, RCP, TNF-a, IL-10,
IL-8 y CD25 on days 0, 1, 3, 5 and 21 post-surgery will be
recorded. These values have been selected according to what is
reported in the literature in similar studies.[19–25] Also, these
same values will be recorded pre-operatively at the time surgical
intervention is indicated to show the patient’s baseline
inflammatory status.- Nutritional parameters: albumin, prealbumin and lymphocytes
at the time surgical intervention is indicated and on days 0, 1, 3,
5 and 21.- Hepatic parameters: total bilirubin, alanin-aminotranspherase,
aspartat aminotranspherase, gammaglutamil transpherase and
alkaline phosphatase at the time surgical intervention is
indicated and on days 0, 1, 3, 5 and 21.- Safety: INR, prothrombin time and platelet count at the time
surgical intervention is indicated and on days 0, 1, 3, 5 and 21.
The total number of blood extractions per patient will be 6.
Clinical data: the following data will be recorded:- Post-surgery complications such as chylothorax, dehiscence,
pneumonia and other infections.- Mortality: from the day of surgery to 1 year following surgery.
- Nutritional support: the amount of EN received by each patient
will be recorded to determinate total calories administered.
2.5.1.2. Quantification of cytokines.- Sample collection: Samples will be centrifugated at 700g an
hour post-extraction. Samples will be aliquoted and stored
frozen at -80°C until analysis (1year). Cytokine values will be
determined by Enzyme-Linked ImmunoSorbent Assay (ELISA).
2.6. Response assessment
2.6.1. Statistical analysis. Descriptive statistics will be
employed for all collected variables data, such as baseline values
for inflammatory, nutritional, hepatic and safety parameters, in
frequency tables. For continuous variables, statistical descrip-
tions will be used (n, average, standard deviation, value range and
median), meanwhile grouped percentages will be used for
categorical variables.
The main objective is to establish the difference between basal
values of inflammatory parameters and values at day 5 post-
randomization, and to assess differences between days 1, 3 and
21. The secondary objectives are to establish the difference
between basal values of morbidity, safety and nutritional
parameters and those values at day 5 post-randomization.
Significance will be calculated using Student’s t test for
matching data or Wilcoxon-test (non-parametric test) depending
on whether normality can be assumed or not. To establish
the differences among the 3 groups for the same period of
time, Student’s t test (parametric test) or Mann Whitney U test6
(non-parametric test) will be used, depending on whether
normality can be assumed or not. For categorical variables,
the chi-square test or the Fisher test will be used when necessary.
The significance level will be established with a 95%
confidence interval (CI). Data will be processed with SPPS v 19.2.7. Adverse events notification
All serious adverse events, regardless of their causal relation,
will be reported to the study monitor immediately, sending a
fax to +34932607884, in a maximum of 1 working day.
According to articles 43 and 44 of the RD1090/2015, which
regulates clinical trials in Spain, and in accordance also with
sections 25 to 27 from the regulatory document concerning
implementation of normal clinical trials (6th version, May
2008), the monitor will be responsible for communicating every
serious and unexpected adverse event to the competent Health
Authorities. (http://www.aemps.es/actividad/invClinica/ensayo
sClinicos.htm).2.8. Monitoring
Monitoring tasks will be carried out by a monitoring company
hired for this purpose. The person responsible for monitoring this
study will have access to any clinical data required for the
conduct of the trial and to all interim results. There will be 4
monitor-auditing visits that will take place at the beginning of the
study prior to the first patient recruitment, when half of the
patients are recruited, and when the follow-up of the last patient
is finished, which means the end of the study. The monitor will be
responsible for communicating any adverse events to the health
authorities.3. Discussion
These days, v-3 fatty acids are playing an increasingly emergent
role in artificial nutrition, due to the discovery of their
protective and immunomodulatory effects in inflammatory
processes.[20–26]
It is known that the PUFAs of cellular membranes are
precursors of secondary messengers that can act as pro-
inflammatory or as anti-inflammatory agents, and physiological
response depends on the balance of the lipid composition of
membranes.[12,15,16]
The study of these secondary messengers in esophagectomized
patients, may establish their correlation with the patient’s clinical
progress, depending on the capacity of the v-3 fatty acids to
modulate these secondary messengers.
This study combines high-risk patients with considerable
inflammatory response with intravenous administration of
significant quantities of v-3 fatty-acids, and may lead to the
discovery of a new pharmacological strategy that is simple, safe
and cost-effective. It will also provide useful data through the
study of a new mediator.4. Trial status
Protocol version 2 of 06/08/2017.
Patient recruitment began: 11/05/2018.
Approximate date of completed patient recruitment: 01/05/
2022 (first approximate date was calculated on 01/05/2020,
however it has suffered a delay because of COVID-19).
Suárez-Lledó et al. Medicine (2021) 100:25 www.md-journal.comAcknowledgments
We want to thank all the health personnel involved in the care of
esophagectomized patients.
We thank CERCA Programme / Generalitat de Catalunya for
institutional supportAuthor contributions
MBT, JLT, ELB, and ASL conceived the work. ASL, MBT, ELB
and JLT contributed equally to the writing of this study protocol.
MFA, LFT, MMM, NVC, GCC, JBM, EPC, SNV contributed
equally to the final review of this study protocol.
Conceptualization: Ana Suárez-Lledó, Josep M. Llop Talaveron,
María B. Badia Tahull.
Data curation: Ana Suárez-Lledó.
Formal analysis: Ana Suárez-Lledó, Josep M. Llop Talaveron,
Jordi Bas Minguet, María B. Badia Tahull.
Investigation:Ana Suárez-Lledó, Elisabet Leiva Badosa, Jordi Bas
Minguet.
Methodology: Ana Suárez-Lledó, Elisabet Leiva Badosa, Josep
M. Llop Talaveron, Leandre Farran Teixidor, Jordi Bas
Minguet, María B. Badia Tahull.
Project administration: Elisabet Leiva Badosa,Mónica Fernández
Alvarez, Leandre Farran Teixidor, Monica Miró Martín,
María Nuria Virgili Casas, Glòria Creus Costas, Jordi Bas
Minguet, Sergio Navarro Velazquez, Elisabet Poyatos
Canton, María B. Badia Tahull.
Resources:Mónica Fernández Alvarez, Leandre Farran Teixidor,
Monica Miró Martín, María Nuria Virgili Casas, Glòria
Creus Costas, Jordi Bas Minguet, Sergio Navarro Velazquez,
Elisabet Poyatos Canton, María B. Badia Tahull.
Supervision: Ana Suárez-Lledó, Elisabet Leiva Badosa, Josep M.
Llop Talaveron, María B. Badia Tahull.
Validation: Ana Suárez-Lledó, María B. Badia Tahull.
Writing – original draft: Ana Suárez-Lledó.
Writing – review & editing: Ana Suárez-Lledó, Elisabet Leiva
Badosa, Josep M. Llop Talaveron, Mónica Fernández
Alvarez, Leandre Farran Teixidor, Monica Miró Martín,
María Nuria Virgili Casas, Glòria Creus Costas, Jordi Bas
Minguet, Sergio Navarro Velazquez, Elisabet Poyatos
Canton, María B. Badia Tahull.References
[1] Park DP, Welch CA, Harrison DA, et al. Outcomes following
oesophagectomy in patients with oesophageal cancer: a secondary
analysis of the ICNARC Case Mix Programme Database. Crit Care
2009;13(Suppl 2):S1.
[2] Nakamura M, Iwahashi M, Takifuji K, et al. Optimal dose of
preoperative enteral immunonutrition for patients with esophageal
cancer. Surg Today 2009;39:855–60.
[3] Sultan J, Griffin SM, Di Franco F, et al. Randomized clinical trial of
omega-3 fatty acid supplemented enteral nutrition versus standard
enteral nutrition in patients undergoing oesophagogastric cancer surgery.
Br J Surg 2012;99:346–55.
[4] Yang C-FJ, Lee M, Valim C, et al. Persistent alanine aminotransferase
elevations in children with parenteral nutrition-associated liver disease. J
Pediatr Surg 2009;44:1084–7. discussion 1087–1088.
[5] Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the
anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev
2010;68:280–9.7
[6] Seki H, Tani Y, AritaM.Omega-3 PUFA derived anti-inflammatory lipid
mediator resolvin E1. Prostaglandins Other Lipid Mediat 2009;89:
126–30.
[7] Xu J, Yunshi Z, Li R. Immunonutrition in surgical patients. Curr Drug
Targets 2009;10:771–7.
[8] Tsekos E, Reuter C, Stehle P, Boeden G. Perioperative administration of
parenteral fish oil supplements in a routine clinical setting improves
patient outcome after major abdominal surgery. Clin Nutr Edinb Scotl
2004;23:325–30.
[9] Akbarshahi H, Andersson B, Nordén M, Andersson R. Perioperative
nutrition in elective gastrointestinal surgery – potential for improvement?
Dig Surg 2008;25:165–74.
[10] Braga M, Gianotti L, Radaelli G, et al. Perioperative immunonutrition in
patients undergoing cancer surgery: results of a randomized double-blind
phase 3 trial. Arch Surg 1999;134:428–33.
[11] Lobo DN, Williams RN, Welch NT, et al. Early postoperative
jejunostomy feeding with an immune modulating diet in patients
undergoing resectional surgery for upper gastrointestinal cancer: a
prospective, randomized, controlled, double-blind study. ClinNutr
2006;25:716–26.
[12] Gunerhan Y, Koksal N, Sahin UY, Uzun MA, Ekşioglu-Demiralp E.
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